The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Mar. 27, 2012
Filed:
Feb. 22, 2011
Edward Turos, Wesley Chapel, FL (US);
Burt E. Anderson, Valrico, FL (US);
Ryan Scott Cormier, Tampa, FL (US);
John C. Thomas, Lake City, FL (US);
Rebecca J. Kapolka, Pinellas Park, FL (US);
Glenn Roma, Tampa, FL (US);
Edward Turos, Wesley Chapel, FL (US);
Burt E. Anderson, Valrico, FL (US);
Ryan Scott Cormier, Tampa, FL (US);
John C. Thomas, Lake City, FL (US);
Rebecca J. Kapolka, Pinellas Park, FL (US);
Glenn Roma, Tampa, FL (US);
University of South Florida, Tampa, FL (US);
Abstract
species are facultative intracellular pathogens responsible for a range of diseases in animals and in humans. A selection of N-acyl ciprofloxacin analogues, chemically synthesized from ciprofloxacin, have been tested in vitro for activity againstspecies as models for therapeutic development. Ninestrains, including five of, two of, and one each ofand, have been tested for susceptibility to different N-acyl ciprofloxacin derivatives. Several techniques have been used to test the in vitro antibacterial activity of the derivatives. Seven of them, labeled RC4-125, RC4-143, RC4-147, RC5-28, RC5-29, RC5-32 and RC5-69 showed significant intracellular anti-activity. These synthetically derived N-acyl ciprofloxacin derivatives may be useful in the therapeutic treatment of infections caused by